To the Editor I want to congratulate Leberfinger et al¹ for their systematic review including 95 patients with breast implant–associated anaplastic large cell lymphoma. The underlying mechanism is briefly described as chronic inflammation from indolent infections, leading to malignant transformation of T cells that are anaplastic lymphoma kinase negative and CD30 positive. However, the authors did not give detailed information about the clinicopathological characteristics of the chemotherapy schedules and radiotherapy that patients with breast cancer received, which might be risk factors for the development of breast implant–associated anaplastic large cell lymphoma. Some breast cancer subtypes, such as triple-negative or human epidermal growth factor receptor 2–positive breast cancer, are more immunogenic and tend to develop more breast implant–associated anaplastic large cell lymphoma.²

致编辑，我要祝贺 Leberfinger 等人¹他们的系统评价包括 95 名乳房植入物相关的间变性大细胞淋巴瘤患者。其潜在机制被简要描述为惰性感染引起的慢性炎症，导致间变性淋巴瘤激酶阴性和 CD30 阳性的 T 细胞恶性转化。然而，作者没有提供有关乳腺癌患者接受的化疗方案和放疗的临床病理学特征的详细信息，这可能是乳房植入物相关间变性大细胞淋巴瘤发展的危险因素。一些乳腺癌亚型，例如三阴性或人表皮生长因子受体 2 阳性乳腺癌，具有更高的免疫原性，并且倾向于发展更多与乳房植入物相关的间变性大细胞淋巴瘤。²